Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Enspryng (satralizumab)
- eplerenone
Interactions between your drugs
eplerenone satralizumab
Applies to: eplerenone, Enspryng (satralizumab)
Satralizumab may decrease the blood levels and effects of eplerenone. You may need a dose adjustment if you have been receiving eplerenone and are starting treatment with satralizumab. Likewise, if you have been receiving both medications, the dose of eplerenone may need to be adjusted when satralizumab is discontinued. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
eplerenone food
Applies to: eplerenone
Consumption of grapefruit, grapefruit juice, and supplements that contain grapefruit should be avoided during treatment with eplerenone as they may increase the blood levels and effects of eplerenone. High blood levels of eplerenone can increase the risk of side effects including hyperkalemia (high blood potassium), which in severe cases can lead to kidney failure, muscle paralysis, irregular heart rhythm, and cardiac arrest. You may be more likely to develop hyperkalemia during treatment with eplerenone if you are elderly, dehydrated, or have kidney disease, diabetes, or advanced heart failure. You should seek medical attention if you experience nausea, vomiting, weakness, confusion, tingling of the hands and feet, feelings of heaviness in the legs, a weak pulse, or a slow or irregular heartbeat, as these may be symptoms of hyperkalemia. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Uplizna
Uplizna is used to treat adults with neuromyelitis optica spectrum disorder (NMOSD) or ...
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Soliris
Soliris infusion is used to treat paroxysmal nocturnal hemoglobinuria (PNH) or neuromyelitis optica ...
Bkemv
Bkemv (eculizumab-aeeb) is an interchangeable biosimilar to Soliris which may be used to treat ...
Epysqli
Epysqli (eculizumab-aagh), a biosimilar to Soliris, targets the complement system to treat ...
Inebilizumab
Inebilizumab is used to treat adults with NMOSD (neuromyelitis optica spectrum disorder) who are ...
Ravulizumab
Ravulizumab-cwvz is used to treat myasthenia gravis (gMG), hemolytic uremic syndrome (aHUS) ...
Eculizumab
Eculizumab (brand names Soliris, Bkemv, and Epysqli) is used to treat paroxysmal nocturnal ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.